Rocket Pharmaceuticals, Inc. officer and director Gaurav Shah filed a Form 144 notice of proposed sale on November 18, 2026, covering 2,216 shares of common stock to be sold through Fidelity Brokerage Services LLC on NASDAQ.
Key Highlights
- Proposed sale: 2,216 shares of Rocket Pharmaceuticals common stock with an aggregate market value of $4,827.56, according to the filing.
- Source of shares: The shares were acquired on November 16, 2026 through restricted stock vesting from the issuer, with payment classified as compensation.
- Tax-related purpose: The filing states the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
- Shares outstanding: The filing reports 111,660,283 shares of common stock outstanding.
- Prior sales in past 3 months: Shah sold 2,293 shares on August 18, 2026 for gross proceeds of $7,753.55, and 3,020 shares on November 13, 2026 for gross proceeds of $6,795.91.
- Relationship to issuer: Gaurav Shah is identified in the filing as both an officer and a director of Rocket Pharmaceuticals, Inc.
Gaurav Shah's Proposed Share Sale at Rocket Pharmaceuticals
According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 18, 2026, Gaurav Shah, an officer and director of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), intends to sell 2,216 shares of the company's common stock. The proposed sale is to be executed through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, with an approximate sale date of November 18, 2026. The aggregate market value of the shares to be sold is listed as $4,827.56 in the filing.
The filing discloses that the shares proposed for sale were acquired on November 16, 2026 via restricted stock vesting from the issuer. The nature of payment is described as compensation. The filing's remarks section states that the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution," providing the stated rationale for the transaction.
As required by Form 144, the filing also discloses Shah's sales of Rocket Pharmaceuticals common stock during the preceding three months. Those transactions consisted of a sale of 2,293 shares on August 18, 2026 generating gross proceeds of $7,753.55, and a sale of 3,020 shares on November 13, 2026 generating gross proceeds of $6,795.91. The total shares of common stock outstanding at the time of the filing are reported as 111,660,283.
What Was Disclosed
Rocket Pharmaceuticals officer and director Gaurav Shah filed a Form 144 notice to sell 2,216 shares of common stock, acquired through restricted stock vesting on November 16, 2026, citing a tax obligation from a vested equity award as the stated purpose of the sale.




Please wait processing your request...